NCT00726856已完成不适用
A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,200
- 主要终点
- Evaluation of the change in LDL-C levels after treatment
研究概览
简要总结
This retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their normal standard of care. This study assesses the percentage of patients who achieve LDL-C target goals and also evaluates the patient compliance to treatment.
详细描述
Retrospective medical chart review
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient was > 20 years and < 75 years of age on the index date*
- •Patient diagnosed with dyslipidemia who did not respond adequately based on NCEP ATP III target to previous lipid lowering treatment, and have received dual inhibition therapy, such as ezetimibe plus statins, ezetimibe plus fenofibrate or ezetimibe alone, for at least 3 months
- •Patient has at least one Total Cholesterol and LDL-C measurements at baseline and 3 months after initiating the dual inhibition therapy.
- •Patient has the following records documented in the chart during the data collection period:
- •Medical history and co morbidities (if available)
- •Total Cholesterol and LDL-C. test results before and after initiating the dual inhibition therapy
- •Prescription information of lipid-lowering dual inhibition regimens NOTE: * Index date: the date of initiating dual inhibition therapy
排除标准
- •Patients who do not meet all the inclusion criteria will be excluded from this survey.
- •Patients who were enrolled in other clinical trial observing specific study procedures which deviates from normal practice will not be included in this study.
研究组 & 干预措施
Patients
patients with dyslipidemia
干预措施: Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate (Drug)
结局指标
主要结局
Evaluation of the change in LDL-C levels after treatment
时间窗: 3 months
次要结局
- Assessment of the percentage of patients who attain their National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III target for LDL-C(3 months)
- Assessment of patient compliance by evaluating the length of stay on therapy(3 months)
- Comparison of the patient comorbidities among populations gathered from different levels of hospitals and specialties(3 months)
- Evaluation of safety and tolerability in patients receiving dual inhibition therapy(3 months)
研究者
相似试验
已完成
4 期
Ezetimibe and Statins on Postprandial Lipemia in Type 2 DiabetesPostprandial LipemiaType 2 DiabetesNCT00699023Federico II University13
终止
3 期
Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)AtherosclerosisHypercholesterolemiaNCT00651391Organon and Co28
已完成
3 期
A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)Coronary DiseaseNCT00551447Organon and Co616
已完成
3 期
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)HypercholesterolemiaNCT00276458Organon and Co196
已完成
3 期
Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)Hyperlipoproteinemia Type IIAtherosclerosisHypercholesterolemiaNCT00552097Organon and Co720